Luke Neilans, MD
Critical Care Medicine · Charlotte, NCNPI 1952621427
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (53.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Genentech, Inc. at 53.5% of the total. Reporting peaked in 2020 at $1,045 and has fallen 97.7% since, to $24 in 2025.
Across 34 payments — averaging $55.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- United Therapeutics Corporation$173
- Boehringer Ingelheim$130
- GSK$117
- Melinta Therapeutics, LLC$96
- Baxter Healthcare$81
- plus $272 from 11 others
What the payments were for
- Grants$1,00053%
- Food & beverage$83044%
- Education$402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $1,000 |
| United Therapeutics Corporation | 2 | $173 |
| Boehringer Ingelheim | 1 | $130 |
| GSK | 6 | $117 |
| Melinta Therapeutics, LLC | 6 | $96 |
| Baxter Healthcare | 4 | $81 |
| Sanofi | 2 | $53 |
| AstraZeneca | 3 | $50 |
| Haemonetics Corporation | 1 | $24 |
| Amgen | 1 | $24 |
| Shionogi Inc | 1 | $24 |
| Nabriva Therapeutics, PLC | 1 | $21 |
| Insmed, Inc. | 1 | $20 |
| Electromed, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $13 |
| Merck | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,870 in reported general payments places this provider in the 75th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $399,044 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 240 | $200,155 |
| Pirfenidone | 44 | $85,291 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $65,977 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $31,731 |
| Incruse ElliptaUmeclidinium Bromide | 88 | $30,150 |
| Spiriva RespimatTiotropium Bromide | 45 | $25,269 |
| Spiriva HandihalerTiotropium Bromide | 15 | $17,930 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $16,756 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $16,509 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $11,583 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 232 | $6,878 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $5,043 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,574 |
| Mycophenolate Mofetil | 14 | $1,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $130 | $424,31376 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $117 | $278,793434 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $50 | $82,485142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Charlotte
- Rabih BecharaCharlotte$453K
- Alan HeffnerCharlotte$326K
- John DotyCharlotte$37K
- Alfred PapaliCharlotte$10K
- Amar PanchalCharlotte$8K
- Lacey SpanglerCharlotte$3K
- Jeffrey WallsCharlotte$2K
- Sachin HansaliaCharlotte$2K
- Kimberly McCreaCharlotte$2K
- James RobertsCharlotte$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.